As we move through 2026, the industry is undergoing a "Financial Transformation." This year, the Cell and Gene Therapy Market has achieved a "Payer Milestone," where over 60% of new therapy contracts in the U.S. and Europe are now "Outcome-Based." This means the manufacturer only receives full payment if the patient remains disease-free after one year. This is proving essential for the 2026...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Portuguese
Romaian
Portuguese (Brazil)
china